Peapod Lane Capital LLC Takes Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Peapod Lane Capital LLC bought a new position in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 642,193 shares of the company's stock, valued at approximately $867,000. Peapod Lane Capital LLC owned 1.05% of Pliant Therapeutics as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Swiss National Bank lifted its stake in Pliant Therapeutics by 1.6% in the 4th quarter. Swiss National Bank now owns 95,700 shares of the company's stock worth $1,260,000 after purchasing an additional 1,500 shares in the last quarter. Atria Investments Inc lifted its stake in Pliant Therapeutics by 18.1% in the 4th quarter. Atria Investments Inc now owns 11,821 shares of the company's stock worth $156,000 after purchasing an additional 1,812 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Pliant Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 459,384 shares of the company's stock worth $6,050,000 after purchasing an additional 2,721 shares in the last quarter. MetLife Investment Management LLC lifted its stake in Pliant Therapeutics by 11.9% in the 4th quarter. MetLife Investment Management LLC now owns 36,788 shares of the company's stock worth $484,000 after purchasing an additional 3,925 shares in the last quarter. Finally, ProShare Advisors LLC lifted its stake in Pliant Therapeutics by 31.8% in the 4th quarter. ProShare Advisors LLC now owns 18,931 shares of the company's stock worth $249,000 after purchasing an additional 4,570 shares in the last quarter. Institutional investors own 97.30% of the company's stock.

Pliant Therapeutics Price Performance

Shares of NASDAQ PLRX traded up $0.01 during mid-day trading on Friday, hitting $1.41. 581,363 shares of the company's stock traded hands, compared to its average volume of 1,195,585. The company's 50-day moving average is $1.37 and its two-hundred day moving average is $3.98. The company has a market capitalization of $86.56 million, a P/E ratio of -0.39 and a beta of 1.30. Pliant Therapeutics, Inc. has a 1 year low of $1.10 and a 1 year high of $16.10.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "neutral" rating on shares of Pliant Therapeutics in a research note on Tuesday, March 18th. Twelve research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $13.31.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.